Revised MRPs of 1,364 Anti-Cancer Formulations Come into Effect From Today

Key Highlights:

• The National Pharmaceutical Pricing Authority (NPPA) capped trade margins on 137 anti-cancer drugs.
• Revised Maximum Retail Prices (MRPs) for 1,364 anti-cancer formulations came into effect from November 9, 2026.
• This measure is expected to result in an estimated annual consumer saving of ₹3,540.38 crore.
• Many brands reported significant price reductions, with the highest reported reduction being 96.45%.

Detailed Insights:

• The decision to cap trade margins was based on recommendations from an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health & Family Welfare.
• This initiative aims to enhance the affordability and accessibility of crucial anti-cancer medicines for patients.
• Consumers can verify the revised prices through the Pharma Sahi Daam mobile app or the NPPA website.
• Grievances regarding overcharging can be registered via the Pharma Jan Samadhan portal or the NPPA helpline.

Key Concepts Involved:

• National Pharmaceutical Pricing Authority (NPPA): A government regulatory agency that fixes and revises prices of controlled bulk drugs and formulations, and enforces drug price control orders.
• Maximum Retail Price (MRP): The highest price at which a product can be sold to the consumer, inclusive of all taxes.
• Trade Margins: The difference between the price at which a manufacturer sells a drug to a wholesaler and the price at which the wholesaler sells it to a retailer.